# Dxome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dxome

- Industry: Healthcare IT
- Headquarters: Seongnam, South Korea
- Website: www.dxome.com/
- Total disclosed funding: $19M
- Latest round: Series B (Feb 9, 2021)
- Investors on record: 9

## About

Based in Gyeonggi-do, South Korea, and founded in 2017, DXOME CO., LTD., trading as Dxome, operates as a healthcare technology company that offers screening panels and detection kits for human and infectious diseases, led by its CEO, Choi, Jong Rak. The company has its research and development center and manufacturing plant in Seoul. 

The company's platform offers clinically actionable insights for personalized treatment through screening panels and detection kits. Its product line includes DxSeq, a cloud-based analysis system that uses Next-Generation Sequencing (NSG); DxReal, which provides a diagnosis of infectious and human diseases through real-time and multiplex PCR processes; and DxTUBE, a blood collection tube that provides prolonged preservation of cfDNA.

## Funding rounds

- Series B, Feb 9, 2021, $14M — Korea Development Bank, Industrial Bank of Korea, ID Ventures, SV Investment, Kolon Investment, T Investment
- Series A, Mar 14, 2019, $5.3M — AJU IB Investment, ID Ventures, SV Investment, Kiwoom Investment, Green Cross LabCell Corporation

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- ID Ventures (https://capitalatlas.ai/funds/id-ventures) — Series A, Series B
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A, Series B
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A
- Green Cross LabCell Corporation — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Industrial Bank of Korea — Series B
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series B
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series B